Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma

Current Cancer Drug Targets

Volumn 7, Issue 1, 2007, Pages 109-120

  Davidson, Ben ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemotherapy; Effusion; Metastasis; Ovarian carcinoma; Prognosis; Tumor progression

Indexed keywords

CADHERIN; CHEMOKINE RECEPTOR; HLA E ANTIGEN; HLA G ANTIGEN; INTEGRIN; KALLIKREIN; KALLIKREIN 4; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER MODEL; CANCER RESEARCH; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; METASTASIS; NONHUMAN; OVARY CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; TUMOR IMMUNOLOGY;

CADHERINS; FEMALE; HUMANS; INTEGRINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX METALLOPROTEINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEOMICS; RECEPTOR, NERVE GROWTH FACTOR; RECEPTORS, CHEMOKINE; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847407521     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780006904     Document Type: Review

References (135)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M. J. Cancer Statistics, 2006. CA Cancer J. Clin. 2006, 56, 106-130.
2. Flam, F.; Einhorn, N.; Sjovall, K. Symptomatology of ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 1988, 27, 53-57.
3. Sakai, K.; Kamura, T.; Hirakawa, T.; Saito, T.; Kaku, T.; Nakano, H. Relationship between pelvic lymph node involvement and other disease sites in patients with ovarian cancer. Gynecol. Oncol. 1997, 65, 164-168.
4. Tsuruchi, N.; Kamura, T.; Tsukamoto, N.; Akazawa, K.; Saito, T.; Kaku, T.; To, N.; Nakano H. Relationship between paraaortic lymph node involvement and intraperitoneal spread in patients with ovarian cancer- a multivariate analysis. Gynecol. Oncol. 1993, 49, 51-55.
5. Cormio, G.; Maneo, A.; Parma, G.; Pittelli, M. R.; Miceli, M. D.; Bonazzi, C. Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and literature review. Ann. Oncol. 1995, 6, 571-574.
6. Munkarah, A. R.; Hallum, A. V. 3rd.; Morris, M.; Burke, T. W.; Levenback, C.; Atkinson, E. N.; Wharton, J. T.; Gershenson, D. M. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol. Oncol. 1997, 64, 13-17.
7. Akahira, J. I.; Yoshikawa, H.; Shimizu, Y.; Tsunematsu, R.; Hirakawa, T.; Kuramoto, H.; Shiromizu, K.; Kuzuya, K.; Kamura, T.; Kikuchi, Y.; Kodama, S.; Yamamoto, K.; Sato, S. Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study. Gynecol. Oncol. 2001, 81, 398-403.
8. Holschneider, C. H.; Berek, J. S. Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin. Surg. Oncol. 2000, 19, 3-10.
9. Cannistra, S. A. Cancer of the ovary. N. Engl. J. Med. 2004, 351, 2519-2529.
10. Agarwal, R.; Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3, 502-516.
11. Behrens, J. Cadherins and catenins: Role in signal transduction and tumor progression. Cancer Metastasis Rev. 1999, 18, 15-30.
12. Hajra, K. M.; Fearon, E. R. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 2002, 34, 255-268.
13. Van Aken, E.; De Wever, O.; Correia da Rocha, A. S.; Mareel, M. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch. 2001, 439, 725-751.
14. Risinger, J. I.; Berchuck, A.; Kohler, M. F.; Boyd, J. Mutations of the E-cadherin gene in human gynecologic cancers. Nat. Genet. 1994, 7, 98-102.
15. Palacios, J.; Gamallo, C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res. 1998, 58, 1344-1347.
16. Davidson, B.; Berner, A.; Nesland, J. M.; Risberg, B.; Berner, H. S.; Trope', C. G.; Kristensen, G. B.; Bryne, M.; Flørenes, V. A. Ecadherin and α-, β- and γ-catenin protein expression is upregulated in ovarian carcinoma cells in serous effusions. J. Pathol. 2000, 192, 460-469.
17. Sivertsen, S.; Berner, A.; Michael, C. W.; Bedrossian, B.; Davidson, B. Ovarian carcinoma and malignant mesothelioma cells in effusions have comparable cadherin expression. Acta Cytol. 2006, in press.
18. Darai, E.; Scoazec, J. Y.; Walker-Combrouze, F. Mlika-Cabanne, N.; Feldmann, G.; Madelenat, P.; Potet, F. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: A clinicopathologic study of 60 cases. Hum. Pathol. 1997, 28, 922-928.
19. Faleiro-Rodrigues, C.; Macedo-Pinto, I.; Pereira, D.; Lopes, C. S. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann. Oncol. 2004, 15, 1535-1542.
20. Davidson, B.; Gotlieb, W. H.; Ben-Baruch, G.; Nesland, J. M.; Bryne, M.; Goldberg, I.; Kopolovic, J.; Berner, A. E-cadherin complex protein expression and survival in ovarian carcinoma. Gynecol. Oncol. 2000, 79, 362-371.
21. Elloul, S.; Bukholt Elstrand, M.; Nesland, J. M.; Trope', C. G.; Kvalheim, G.; Goldberg, I.; Reich, R.; Davidson, B. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005, 103, 1631-1643.
22. Nieto, M. A. The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 2002, 3, 155-166.
23. Comijn, J.; Berx, G.; Vermassen, P. Verschueren, K.; van Grunsven, L.; Bruyneel, E.; Mareel, M.; Huylebroeck, D.; van Roy, F. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 2001, 7, 1267-1278.
24. Elloul, S.; Silins, I.; Trope', C. G.; Benshushan, A.; Davidson, B.; Reich, R. Site-dependent expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch. 2006 Oct 6 [Epub ahead of print].
25. Hood, J. D.; Cheresh, D. A. Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2002, 2, 91-100.
26. Sanders, R. J.; Mainiero, F.; Giancotti, F. P. The role of integrins in tumorigenesis and metastasis. Cancer Invest. 1998, 16, 329-344.
27. Moser, T. L.; Pizzo, S. V.; Bafetti, L. M.; Fishman, D. A.; Stack, M. S. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the ?2?1 integrin. Int. J. Cancer 1996, 67, 695-701.
28. Strobel, T.; Cannistra, S. A. β1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol. Oncol. 1999, 73, 362-367.
29. Lessan, K.; Aguiar, D. J.; Oegema, T. Siebenson, L.; Skubitz, A. P. CD44 and β1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am. J. Pathol. 1999, 154, 1525-1537.
30. Davidson, B.; Goldberg, I.; Reich, R.; Tell, L.; Dong, H. P.; Trope', C. G.; Risberg, B.; Kopolovic, J. The αv and β1 integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol. Oncol. 2003, 90, 248-257.
31. Givant-Horwitz, V.; Davidson, B.; van de Putte, G.; Dong, H. P.; Goldberg, I.; Amir, S.; Kristensen, G. B.; Reich, R. Expression of the 67kDa laminin receptor and the ?6 integrin subunit in serous ovarian carcinoma. Clin. Exp. Metastasis 2003, 20, 599-609.
32. Skubitz, A. P.; Bast, R. C., Jr.; Wayner, E. A.; Letourneau, P. C.; Wilke, M. S. Expression of α6 and β4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am. J. Pathol. 1996, 148, 1445-1461.
33. Davidson, B.; Konstantinovsky, S.; Nielsen, S.; Dong, H. P.; Berner, A.; Vyberg, M.; Reich, R. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients- a novel model for tumor progression. Clin. Cancer Res. 2004, 10, 7335-7346.
34. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161-174.
35. Bjorklund, M.; Koivunen, E. Gelatinase-mediated migration and invasion of cancer cells. Biochim. Biophys. Acta 2005, 1755, 37-69.
36. Höyhtya7die;, M.; Fridman, R.; Komarek, D.; Porter-Jordan, K.; Stetler-Stevenson, W. G.; Liotta, L. A.; Liang, C. M. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int. J. Cancer 1994, 56, 500-505.
37. Afzal, S.; Lalani, E. N.; Poulsom, R. Stubbs, A.; Rowlinson, G.; Sato, H.; Seiki, M.; Stamp, G. W. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum. Pathol. 1998, 29, 155-165.
38. Naylor, M. S.; Stamp, G. W.; Davies, B. D.; Balkwill, F. R. Expression and activity of MMPS and their regulators in ovarian cancer. Int. J. Cancer 1994, 58, 50-56.
39. Autio-Harmainen, H.; Karttunen, T.; Hurskainen, T.; Höyhtyä, M.; Kauppila, A.; Tryggvason, K. Expression of 72 kilodalton type IV collagenase (Gelatinase A) in benign and malignant ovarian tumors. Lab. Invest. 1993, 69, 312-321.
40. Davidson, B.; Goldberg, I.; Gotlieb, W. H.; Kopolovic, J.; Ben-Baruch, G.; Nesland, J. M.; Berner, A.; Bryne, M.; Reich, R. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin. Exp. Metastasis 1999, 17, 799-808.
41. Davidson, B.; Reich, R.; Berner, A.; Givant-Horwitz, V.; Goldberg, I.; Risberg, B.; Kristensen, G. B.; Trope', C. G.; Bryne, M.; Kopolovic, J.; Nesland, J. M. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur. J. Cancer 2001, 37, 2040-2049.
42. Huang, L. W.; Garrett, A. P.; Bell, D. A.; Welch, W. R.; Berkowitz, R. S.; Mok, S. C. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol. Oncol. 2000, 77, 369-376.
43. Davidson, B.; Goldberg, I.; Berner, A. Nesland, J. M.; Givant-Horwitz, V.; Bryne, M.; Risberg, B.; Kristensen, G. B.; Trope', C. G.; Kopolovic, J.; Reich, R. Expression of membrane-type 1,2 and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. Am. J. Clin. Pathol. 2001, 115, 517-524.
44. Stadlmann, S.; Pollheimer, J.; Moser, P. L.; Raggi, A.; Amberger, A.; Margreiter, R.; Offner, F. A.; Mikuz, G.; Dirnhofer, S.; Moch, H. Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer. Eur. J. Cancer 2003, 39, 2499-2505.
45. Kamat, A. A.; Fletcher, M.; Gruman, L. M.; Mueller, P.; Lopez, A.; Landen, C. N., Jr.; Han, L.; Gershenson, D. M.; Sood, A. K. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin. Cancer Res. 2006, 12, 1707-1714.
46. Kataoka, H.; DeCastro, R.; Zucker, S.; Biswas, C. Tumor cellderived collagenase stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res. 1993, 53, 3154-3158.
47. Guo, H.; Li, R.; Zucker, S.; Toole, B. P. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res. 2000, 60, 888-891.
48. Berditchevski, F.; Chang, S.; Bodorova, J.; Hemler, M. E. Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6. J. Biol. Chem. 1997, 272, 29174-29180.
49. Davidson, B.; Goldberg, I.; Berner, A.; Kristensen, G. B.; Reich, R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin. Exp. Metastasis 2003, 20, 161-169.
50. Davidson, B.; Givant-Horwitz, V.; Lazarovici, P.; Risberg, B.; Nesland, J. M.; Trope', C. G.; Schaefer, E.; Reich, R. Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin. Exp. Metastasis 2003, 20, 621-631.
51. Yousef, G. M.; Diamandis, E. P. The new human kallikrein gene family: structure, function, and association to disease. Endocrine Rev. 2001, 22, 184-204.
52. Davidson, B.; Xi, Z.; Klokk, T. I.; Trope', C. G.; Dørum, A.; Scheistrøen, M.; Saatcioglu, F. Kallikrein 4 expression is upregulated in ovarian carcinoma cells in effusions. Am. J. Clin. Pathol. 2005, 123, 360-368.
53. Fidler, I. J.; Ellis, L. M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994, 79, 185-188.
54. Folkman, J.; Klagsbrun, M. Angiogenic factors. Science 1987, 235, 442-447.
55. Roy, H.; Bhardwaj, S.; Yla-Herttuala, S. Biology of vascular endothelial growth factors. FEBS Lett. 2006, 580, 2879-2887.
56. Ornitz, D. M.; Itoh, N. Fibroblast growth factors. Genome Biol. 2001, 2(3), REVIEWS3005.
57. Grose, R.; Dickson, C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 2005, 16, 179-186.
58. Presta, M.; Dell'Era, P.; Mitola, S.; Moroni, E.; Ronca, R.; Rusnati, M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005, 16, 159-178.
59. Wilson, J.; Balkwill, F. The role of cytokines in the epithelial cancer microenvironment. Semin. Cancer Biol. 2002, 12, 113-120.
60. Homey, B.; Müller, A.; Zlotnik, A. Chemokines: agents for immunotherapy of cancer. Nat. Rev. Immunol. 2002, 2, 175-184.
61. Ramakrishnan, S.; Subramanian, I. V.; Yokoyama, Y.; Geller, M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005, 8, 169-182.
62. Davidson, B.; Goldberg, I.; Kopolovic, J.; Gotlieb, W. H.; Givant-Horwitz, V.; Nesland, J. M.; Berner, A.; Ben-Baruch, G.; Bryne, M.; Reich, R. Expression of angiogenesis-related genes in ovarian carcinoma- a clinicopathologic study. Clin. Exp. Metastasis 2000, 18, 501-507.
63. Davidson, B.; Reich, R.; Kopolovic, J.; Berner, A.; Nesland, J. M.; Kristensen, G. B.; Trope', C. G.; Bryne, M.; Risberg, B.; van de Putte, G.; Goldberg, I. Interleukin-8 and vascular endothelial growth factor mRNA levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin. Exp. Metastasis 2002, 19, 135-144.
64. Konstantinovsky, S.; Nielsen, S.; Vyberg, M.; Kvalheim, G.; Nesland, J. M.; Reich, R.; Davidson, B. Angiogenic molecule expression is downregulated in effusions from breast cancer patients. Breast Cancer Res. Treat. 2005, 94, 71-80.
65. Davidson, B.; Vintman, L.; Zcharia, E.; Bedrossian, C.; Berner, A.; Nielsen, S.; Ilan, N.; Vlodavsky, I.; Reich, R. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin. Exp. Metastasis 2004, 21, 469-476.
66. Dupont, J.; Aghajanian, C.; Sabbatini, P.; Spriggs, D. R. New agents for the treatment of ovarian cancer: the next generation. Int. J. Gynecol. Cancer 2005, 15, 252-257.
67. Barbacid, M. Neurotrophic factors and their receptors. Curr. Opin. Cell Biol. 1995, 7, 148-155.
68. Kaplan, D. R.; Miller, F. D. Signal transduction by the neurotrophin receptors. Curr. Opin. Cell Biol. 1997, 9, 213-221.
69. Patapoutian, A.; Reichardt, L. F. Trk receptors: mediators of neurotrophin action. Curr. Opin. Neurobiol. 2001, 11, 272-280.
70. Kaplan, D. R.; Miller, F. D. Neutrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 2000, 10, 381-391.
71. Teng, K. K.; Hempstead, B. L. Neutrophins and their receptors: signaling trios in complex biological systems. Cell Mol. Life Sci. 2004, 61, 35-48.
72. Nakagawara, A. Trk receptor tyrosine kinases: A bridge between cancer and neural development. Cancer Lett. 2001, 169, 107-114.
73. Shibayama, E.; Koizumi, H. Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues. Am. J. Pathol. 1996, 148, 1807-1818.
74. Fanburg-Smith, J. C.; Miettinen, M. Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneuronal tumors: A study of 1,150 tumors and fetal and adult normal tissues. Hum. Pathol. 2001, 32, 976-983.
75. Davidson, B.; Lazarovici, P.; Ezersky, A.; Nesland, J. M.; Berner, A.; Risberg, B.; Trope', C. G.; Kristensen, G. B.; Goscinski, M.; van de Putte, G.; Reich, R. Expression levels of the NGF receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin. Cancer Res. 2001, 7, 3457-3464.
76. Davidson, B.; Reich, R.; Lazarovici, P.; Nesland, J. M.; Risberg, B.; Trope', C. G.; Flørenes, V. A. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin. Cancer Res. 2003, 9, 2248-2259.
77. Davidson, B.; Reich, R.; Lazarovici, P.; Flørenes, V. A.; Nielsen, S.; Nesland, J. M. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provides the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res. Treat. 2004, 83, 119-128.
78. Davidson, B.; Reich, R.; Lazarovici, P.; Flørenes, V. A.; Risberg, B.; Nielsen, S.; Sert, B.; Bedrossian, C. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 2004, 44, 159-165.
79. Calza, L.; Giardino, L.; Guiliani, A.; Aloe, L.; Levi-Montalcini, R. Nerve growth factor control of neuronal expression of angiogenic and vasoactive factors. Proc. Natl. Acad. Sci. USA 2001, 98, 4160-4165.
80. Cantarella, G.; Lempereur, L.; Presta, M.; Ribatti, D.; Lombardo, G.; Lazarovici, P.; Zappala, G.; Pafumi, C.; Bernardini, R. Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J. 2002, 16, 1307-1309.
81. Flørenes, V. A.; Reich, R.; Lazarovici, P.; Mælandsmo, G. M.; Holm, R.; Davidson, B. Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome. Am. J. Clin. Pathol. 2004, 122, 412-420.
82. Ødegaard, E.; Staff, A. S.; Abeler, V.; Kopolovic, J.; Onsrud, M.; Lazarovici, P.; Davidson, B. The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced stage ovarian carcinoma. Hum. Pathol. 2006. [Epub ahead of print Sep 21 ].
83. Ong, C. H. P.; Bateman, A. Progranulin (Granulin-epithelin precursor, PC-cell derived growth factor, Acrogranin) in proliferation and tumorigenesis. Histol. Histopathol. 2003, 18, 1275-1288.
84. Bhandari, V.; Bateman, A. Structure and chromosomal location of the human granulin gene. Biochem. Biophys. Res. Commun. 1992, 188, 57-63.
85. Shoyab, M.; McDonald, V. L.; Byles, C.; Todaro, G. J.; Plowman, G. D. Epithelins 1 and 2: isolation and characterization of two cysteine-rich growth-modulating proteins. Proc. Natl. Acad. Sci. USA 1990, 87, 7912-7916.
86. Daniel, R.; Daniels, E.; He, Z.; Bateman, A. Progranulin (Acrogranin/ PC-cell derived growth factor/ epithelin precursor) is expressed in the placenta, epidermis, microvasculature and brain during murine development. Dev. Dyn. 2003, 227, 593-599.
87. Zhu, J.; Nathanm C.; Jin, W.; Sim, D.; Ashcroft, G. S.; Wahl, S. M.; Lacomis, L.; Erdjument-Bromage, H.; Tempst, P.; Wright, C. D.; Ding, A. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002, 111, 867-878.
88. Jones, M. B.; Michener, C. M.; Blanchette, J. O.; Kuznetsov, V. A.; Raffeld, M.; Serrero, G.; Emmert-Buck, M. R.; Petricoin, E. F.; Krizman, D. B.; Liotta, L. A.; Kohn, E. C. The Granulin-Epithelin Precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin. Cancer Res. 2003, 9, 44-51.
89. Kamrava, M.; Simpkins, F.; Alejandro, E.; Michener, C.; Meltzer, E.; Kohn, E. C. Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer. Oncogene 2005, 24, 7084-7093.
90. Stevens, E. V.; Raffeld, M.; Espina, V.; Kristensen, G. B.; Trope', C. G.; Kohn, E. C.; Davidson, B. Expression of Xeroderma Pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer 2005, 103, 2313-2319.
91. Denhardt, D. T. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem. J. 1996, 318, 729-747.
92. Garrington, T. P.; Johnson, G. L. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr. Opin. Cell Biol. 1999, 11, 211-218.
93. Fanger, G. R. Regulation of the MAPK family members: Role of subcellular localization and architectural organization. Histol. Histopathol. 1999, 14, 887-894.
94. Chang, L.; Karin, M. Mammalian MAP kinase signalling cascades. Nature 2001, 410, 37-40.
95. Davis, R. J. MAPKs: new JNK expands the group. Trends Biochem. Sci. 1994, 19, 470-473.
96. Camps, M.; Nichols, A.; Arkinstall, S. Dual specificity phosphatases: a gene family for control of MAPK function. FASEB J. 1999, 14, 6-16.
97. Tamura, S.; Hanada, M.; Ohnishi, M.; Katsura, K.; Sasaki, M.; Kobayashi, T. Regulation of stress-activated protein kinase signaling pathways by protein phosphatases. Eur. J. Biochem. 2002, 269, 1060-1066.
98. Givant-Horwitz, V.; Davidson, B.; Lazarovici, P.; Schaefer, E.; Nesland, J. M.; Trope', C. G.; Reich, R. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol. Oncol. 2003, 91, 160-172.
99. Sebolt-Leopold, J. S.; Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 2004, 4, 937-947.
100. Givant-Horwitz, V.; Davidson, B.; Goderstad, J. M.; Nesland, J. M.; Trope', C. G.; Reich, R. The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol. Oncol. 2004, 93, 517-523.
101. Hsu, C. Y.; Bristow, R.; Cha, M. S.; Wang, B. G.; Ho, C. L.; Kurman, R. J.; Wang, T. L.; Shih, Ie. M. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin. Cancer Res. 2004, 10, 6432-6436.
102. Vintman, L.; Nielsen, S.; Berner, A.; Reich, R.; Davidson, B. Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells. Cancer 2005, 103, 2427-2433.
103. Davidson, B.; Konstantinovsky, S.; Kleinberg, L.; Nguyen, M. T. P.; Bassarova, A.; Kvalheim, G.; Nesland, J. M.; Reich, R. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol. Oncol. 2006, 102, 453-461.
104. Svensson, S.; Jirstrom, K.; Ryden, L.; Roos, G.; Emdin, S.; Ostrowski, M. C.; Landberg, G. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 2005, 24, 4370-4379.
105. Milde-Langosch, K.; Bamberger, A. M.; Rieck, G.; Grund, D.; Hemminger, G.; Muller, V.; Loning, T. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br. J. Cancer 2005, 92, 2206-2215.
106. Davidson, B.; Espina, V.; Flørenes, V. A.; Liotta, L. A.; Kristensen, G. B.; Trope', C. G.; Berner, A.; Kohn, E. C. Proteomic profiling of malignant ovarian cancer effusions: survival and injury pathways discriminate clinical outcome. Clin. Cancer Res. 2006, 12, 791-799.
107. Seth, A.; Watson, D. K. Ets transcription factors and their emerging roles in human cancer. Eur. J. Cancer 2005, 41, 2462-2478.
108. Verger, A.; Duterque-Coquillaud, M. When Ets transcription factors meet their partners. BioEssays 2002, 24, 362-370.
109. Sharrocks, A. D. The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2001, 2, 827-837.
110. Sementchenko, V. I.; Watson, D. K. Ets target genes: past, present and future. Oncogene 2000, 19, 6533-6548.
111. Davidson, B.; Reich, R.; Goldberg, I.; Gotlieb, W. H.; Kopolovic, J.; Berner, A.; Ben-Baruch, G.; Bryne, M.; Nesland, J. M. Ets-1 mRNA expression is a novel marker of poor survival in ovarian carcinoma. Clin. Cancer Res. 2001, 7, 551-557.
112. Davidson, B.; Risberg, B.; Goldberg, I.; Nesland, J. M.; Berner, A.; Trope', C. G.; Kristensen, G. B.; Bryne, M.; Reich, R. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am. J. Surg. Pathol. 2001, 25, 1493-1500.
113. Davidson, B.; Goldberg, I.; Gotlieb ,W. H.; Kopolovic, J.; Ben-Baruch, G.; Reich, R. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin. Cancer Res. 2003, 9, 1412-1419.
114. Davidson, B.; Goldberg, I.; Reich, R.; Tell, L.; Baekelandt, M.; Kristensen, G. B.; Berner, A.; Kopolovic, J. The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin. Exp. Metastasis 2004, 21, 191-199.
115. Davidson, B.; Goldberg, I.; Gotlieb, W. H.; Kopolovic, J.; Risberg, B.; Ben-Baruch, G.; Reich, R. Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma- a possible activation pathway? Cancer Metastasis Rev. 2003, 22, 103-115.
116. Algarra, I.; Garcia-Lora, A.; Cabrera, T.; Ruiz-Cabello, F.; Garrido, F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 2004, 53, 904-910.
117. van der Ven, K.; Pfeiffer, K.; Skrablin, S. HLA-G polymorphisms and molecule function- questions and more questions- a review. Placenta 2000, 21(Suppl. A), S86-S92.
118. McMaster, M. T.; Librach, C. L.; Zhou, Y.; Lim, K. H.; Janatpour, M. J.; DeMars, R.; Kovats, S.; Damsky, C.; Fisher, S. J. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J. Immunol. 1995, 154, 3771-3778.
119. Singer, G.; Rebmann, V.; Chen, Y. C.; Liu, H. T.; Ali, S. Z.; Reinsberg, J.; McMaster, M. T.; Pfeiffer, K.; Chan, D. W.; Wardelmann, E.; Grosse-Wilde, H.; Cheng, C. C.; Kurman, R. J.; Shih, I. M. HLA-G is a potential tumor marker in malignant ascites. Clin. Cancer Res. 2003, 9, 4460-4464.
120. Davidson, B.; Elstrand, M. B.; McMaster, M. T.; Berner, A.; Kurman, R. J.; Risberg, B.; Trope', C. G.; Shih, I. M. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol. Oncol. 2005, 96, 42-47.
121. Kleinberg, L.; Flørenes, V. A.; Skrede, M.; Dong, H. P.; Nielsen, S.; McMaster, M. T.; Nesland, J. M.; Shih, I. M.; Davidson. B. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch. 2006, 449, 31-39.
122. Milliken, D.; Scotton, C. J.; Raju, S.; Balkwill, F.; Wilson, J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin. Cancer Res. 2002, 8, 1108-1114.
123. Schutyser, E.; Struyf, S.; Proost, P.; Opdenakker, G.; Laureys, G.; Verhasselt, B.; Peperstraete, L.; Van de Putte, I.; Saccani, A.; Allevena, P.; Mantovani, A.; Van Damme, J. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J. Biol. Chem. 2002, 277, 24584-24593.
124. Zhang, L.; Conejo-Garcia, J. R.; Katsaros, D.; Gimotty, P. A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schlienger, K.; Liebman, M. N.; Rubin, S. C.; Coukos, G. Intratumoral T cells, recurrence, and survival in epithelial ovarian carcinoma. N. Engl. J. Med. 2003, 348, 203-213.
125. Curiel, T. J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J. R.; Zhang, L.; Burow, M.; Zhu, Y.; Wei, S.; Kryczek, I.; Daniel, B.; Gordon, A.; Myers, L.; Lackner, A.; Disis, M. L.; Knutson, K. L.; Chen, L.; Zou, W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10, 942-949.
126. Dong, H. P.; Bunkholt Elstrand, M.; Holth, A.; Silins, I.; Berner, A.; Trope', C. G.; Davidson, B.; Risberg, B. NK and B cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am. J. Clin. Pathol. 2006, 125, 451-458.
127. Davidson, B.; Dong, H. P.; Holth, A.; Berner, A.; Risberg, B. Chemokine receptors are infrequently expressed in malignant or benign mesothelial cells. Am. J. Clin. Pathol. in press.
128. Gorovetz, M.; Baekelandt, M.; Trope', C. G.; Davidson, B.; Reich, R. The clinical role of Phospholipase A2 in advanced-stage ovarian carcinoma. Gynecol. Oncol 2006 [Epub Aug 16].
129. Chen, Y. C.; Pohl, G.; Wang, T. L.; Morin, P. J.; Risberg, B.; Kristensen, G. B.; Yu, A.; Davidson, B.; Shih, Ie. M. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res. 2005, 65, 331-337.
130. nd; Hruban, R. H.; Wang, T. L.; Shih, I. M. Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma. Biochym. Biophys. Acta 2005, 1730, 96-102.
131. Shih, Ie. M.; Sheu, J. J.; Santillan, A.; Nakayama, K.; Yen, M. J.; Bristow, R. E.; Vang, R.; Parmigiani, G.; Kurman, R. J.; Trope', C. G.; Davidson, B.; Wang, T. L. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc. Natl. Acad. Sci. USA 2005, 102, 14004-14009.
132. Park, J. T.; Li, M.; Nakayama, N.; Davidson, B.; Zheng, Z.; Eberhart, C. E.; Kurman, R. J.; Shih, Ie. M.; Wang, T. L. Notch3 gene amplification in ovarian cancer. Cancer Res. 2006, 66, 6312-6318.
133. Nakayama, K.; Nakayama, N.; Davidson, B.; Katabuci, H.; Kurman, R. J.; Velculescu, V. E.; Shih, Ie. M.; Wang, T. L. Homozygous deletion of MKK4 in ovarian serous carcinomas. Cancer Biol. Ther. 2006, 5, 630-634.
134. Davidson, B.; Trope', C. G.; Wang, T. L.; Shih, Ie. M. Expression of the chromatin remodeling factor Rsf-1 in effusions is a novel predictor of poor survival in ovarian carcinoma. Gynecol. Oncol. 2006, Jul 14 [Epub ahead of print].
135. Davidson, B.; Zhang, Z.; Kleinberg, L.; Li, M.; Flørenes, V. A.; Wang, T. L.; Shih, Ie. M. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin. Cancer Res. 2006, 12, 5944-5950.